Recent data from Spratt has suggested improved outcomes with concurrent vs neoadjuvant ADT. However, during the first 1-2 months there is expected prostate shrinkage, which could result in increased doses to rectum or bladder if this occurs during treatment if ADT is given concurrent with RT. How do you account for this?